Literature DB >> 22570457

Pediatric information in drug product labeling.

Aaron N Sachs1, Debbie Avant, Catherine S Lee, William Rodriguez, M Dianne Murphy.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22570457     DOI： 10.1001/jama.2012.3435

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  41 in total

1.  Minimum Requirements for Core Competency in Pediatric Pharmacy Practice.

Authors:  Elizabeth A Boucher; Margaret M Burke; Peter N Johnson; Kristin C Klein; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Nov-Dec

2.  Pediatric off-label use of psychotropic drugs approved for adult use in Japan in the light of approval information regarding pediatric patients in the United States: a study of a pharmacy prescription database.

Authors:  Nanae Tanemura; Maika Asawa; Mayuko Kuroda; Tsuyoshi Sasaki; Yoshiaki Iwane; Hisashi Urushihara
Journal:  World J Pediatr       Date:  2018-11-30       Impact factor: 2.764

3.  Analysis of pediatric clinical drug trials for neuropsychiatric conditions.

Authors:  Srinivas Murthy; Kenneth D Mandl; Florence Bourgeois
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

4.  Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research.

Authors:  Angela S Czaja; Pamela D Reiter; M Lynn Schultz; Robert J Valuck
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

5.  Who cares about a label? The effect of pediatric labeling changes on prescription drug utilization.

Authors:  Christopher Ody; Matt Schmitt
Journal:  Int J Health Econ Manag       Date:  2019-03-18

Review 6.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-07

7.  2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Authors:  Craig A Sable; D Dunbar Ivy; Robert H Beekman; Helene D Clayton-Jeter; Kathy J Jenkins; William T Mahle; William R Morrow; Mary Dianne Murphy; Robert M Nelson; Geoffrey L Rosenthal; Norman Stockbridge; David L Wessel
Journal:  J Am Coll Cardiol       Date:  2017-06-29       Impact factor: 24.094

8.  Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.

Authors:  Cécile Ollivier; Andrew Thomson; Efthymios Manolis; Kevin Blake; Kristin E Karlsson; Catherijne A J Knibbe; Gérard Pons; Robert Hemmings
Journal:  Br J Clin Pharmacol       Date:  2019-02-28       Impact factor: 4.335

9.  Drug labeling and exposure in neonates.

Authors:  Matthew M Laughon; Debbie Avant; Nidhi Tripathi; Christoph P Hornik; Michael Cohen-Wolkowiez; Reese H Clark; P Brian Smith; William Rodriguez
Journal:  JAMA Pediatr       Date:  2014-02       Impact factor: 16.193

10.  Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review.

Authors:  Kazeem A Oshikoya; Gerold T Wharton; Debbie Avant; Sara L Van Driest; Norman E Fenn; Allison Lardieri; Edwin Doe; Beena G Sood; Carol Taketomo; Phuong Lieu; Lilly Yen; Ann W McMahon
Journal:  Paediatr Drugs       Date:  2019-02       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.